Grantham Mayo Van Otterloo & Co. LLC Takes Position in Moderna, Inc. (NASDAQ:MRNA)

Grantham Mayo Van Otterloo & Co. LLC bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 547,812 shares of the company’s stock, valued at approximately $22,778,000. Grantham Mayo Van Otterloo & Co. LLC owned about 0.14% of Moderna at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB increased its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new position in Moderna during the fourth quarter worth about $37,000. Venturi Wealth Management LLC increased its position in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares during the last quarter. Crowley Wealth Management Inc. acquired a new position in Moderna during the fourth quarter worth approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its stake in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares during the period. Institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Barclays lowered shares of Moderna from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a report on Tuesday, February 18th. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, UBS Group dropped their price target on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $59.00.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $25.11 on Friday. The company has a 50 day simple moving average of $33.55 and a 200 day simple moving average of $42.80. Moderna, Inc. has a 1 year low of $23.76 and a 1 year high of $170.47. The firm has a market cap of $9.71 billion, a PE ratio of -2.71 and a beta of 2.23.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.